{"name":"Dynavax Technologies","slug":"dynavax","ticker":"DVAX","exchange":"NASDAQ","domain":"dynavax.com","description":"Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epide","hq":"Emeryville, CA","founded":0,"employees":"405","ceo":"Ryan Spencer","sector":"Vaccines / Adjuvant Technology","stockPrice":15.5,"stockChange":0,"stockChangePercent":0,"marketCap":"$1.8B","metrics":{"revenue":680000000,"revenueGrowth":17.7,"grossMargin":61.6,"rdSpend":61550000,"netIncome":27309000,"cash":647814976,"dividendYield":0,"peRatio":47,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"Heplisav-B patent cliff ($1.2B at risk)","drug":"Heplisav-B","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"HEPLISAV","genericName":"HEPLISAV","slug":"heplisav","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"HEPLISAV","genericName":"HEPLISAV","slug":"heplisav","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[{"date":"2023-02-22","type":"regulatory","headline":"Dynavax Announces FDA Approval of Heplisav-B for Adults 18-70 Years Old","summary":"The FDA approved Heplisav-B, a hepatitis B vaccine, for adults 18-70 years old.","drugName":"Heplisav-B","sentiment":"positive"},{"date":"2022-11-14","type":"deal","headline":"Dynavax Announces Collaboration with GSK to Develop COVID-19 Vaccine","summary":"Dynavax partnered with GSK to develop a COVID-19 vaccine candidate, SD-06.","drugName":"SD-06","sentiment":"positive"},{"date":"2022-08-09","type":"earnings","headline":"Dynavax Reports Second Quarter 2022 Financial Results","summary":"Dynavax reported its second-quarter 2022 financial results, with revenue of $44.8 million.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-02-03","type":"pipeline","source":"simplywall.st","summary":"Assessing Dynavax Technologies (DVAX) Valuation After Recent Share Price Momentum And Ongoing Pipeline Investment - simplywall.st","headline":"Assessing Dynavax Technologies (DVAX) Valuation After Recent Share Price Momentum And Ongoing Pipeline Investment","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-01","type":"pipeline","source":"simplywall.st","summary":"Is Dynavax Technologies (DVAX) Pricing Reflect Its Biotech Role And Recent Share Performance - simplywall.st","headline":"Is Dynavax Technologies (DVAX) Pricing Reflect Its Biotech Role And Recent Share Performance","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-31","type":"deal","source":"simplywall.st","summary":"Sanofi Buyout Of Dynavax Recasts Adult Vaccine Growth For Shareholders - simplywall.st","headline":"Sanofi Buyout Of Dynavax Recasts Adult Vaccine Growth For Shareholders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQajNoNldST2EyLTdNZF9wNi1fTlhXRENxNy1Qa2J6VkdhNkh2UEZ6N1RrQ294ajBUbkRFaGl3bEF0X3NBdkE4LU5uVzFLQnBtcU5SZlZaYTJnU3lqX2NZVTlLaVphcGpGQ05KeUNlQ3o4M1UwcHJ2MFZWRWdaRHpKcUhWQlNfNmkxXzh5aHlLYVZTQVlGUTlMQ0w5aUJXZXVJUlNjX29KWnlETWFfanE5WXZSNm90MVZuQUE?oc=5","date":"2026-01-02","type":"deal","source":"BioPharma APAC","summary":"Sanofi To Acquire Dynavax For $15.50 Per Share In $2.2 Billion All Cash Deal - BioPharma APAC","headline":"Sanofi To Acquire Dynavax For $15.50 Per Share In $2.2 Billion All Cash Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPRUc3TTRMejZwR3dPcmVvY3hQLUxuMTNiVGU2UVVTcFNOZUwyNUxmcHVPR2d4anRLMUtTSGRxNzh2YU9zZmZUYmk5Um5RbkxBeE51STEtdURaaGFDZEZCMnh6UGp6bDZFM3JwZkFMd2tsU0Qyc3hnNlFVOGtpdk9fUUh4T2pxWGtPZ3FpRUR2a1pEME9CeGxKVV95b3U1elpqMUtuYnd30gGuAUFVX3lxTE1LeDk1RUdJVFJ1RklQQk1WTHBqUjJqM2JTMGFaY2s4MGhJTUVEZVp5TlJXVEhPeW94WlhjMlcxUWw5OWV2ZWJkeTlUakIzVk9TNGFJYURGLUhWdW5KWHcxTV9Xd001bTZYX2dTSXM0VlZDanFOMnZOdkJtajZDc0ltR09zRHBDUXFyMHd0bXpmX3N4WnAwSm9jU0lkWTFrd3FaQzRlS3dxN3NVZHlSQQ?oc=5","date":"2025-12-28","type":"deal","source":"Insider Monkey","summary":"Sanofi (SNY) to Acquire Dynavax Technologies Corporation (DVAX) - Insider Monkey","headline":"Sanofi (SNY) to Acquire Dynavax Technologies Corporation (DVAX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQMkJ3N0tueUxtam1YWXYxN1VUMnlWWmpVNFY4emVuOHQ3N3l3cTMzbmYwVEZOVi11cnFUQUNTMHNiMGpxYURCUzNSX25YMUs2MWpWWV90S29RUU9jV01xcnJma1VadFZKMXNVVjlZS1hQUHI2aEpBNWFONGZjWlpjQlF1UUQ5QmVFcjJCWm0yMFJPc05VbEEzeTJaeXRGQl9iWXV6LXlaN1A0ek5BMXI3S19XYl9QM0hlbTRuc2V6Z1UtZnVtTEE?oc=5","date":"2025-12-25","type":"deal","source":"Trefis","summary":"Dynavax Stock (+38%) : Sanofi Buyout Validates Vaccine Pipeline - Trefis","headline":"Dynavax Stock (+38%) : Sanofi Buyout Validates Vaccine Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQdTVaOEtKQ1RibUtPUi1HOTJNclRkUVltWWlDY2RRdUN5QjV4NTNIRjVBa3FKNlNrVk9GeWtoamhXd3pNOWZWSFBTMzVOR0FERkFxMk9LSFJBTGdtQTU5SzR0cUlscFJybWZaTUQzcGRGckhQcTIyYXRHTW84MTFlS0Y0Yi1INkM2aDFFZHBvVGxJMmU4NFJRbTFBdUkzdXg0ZHFRRHl1a3lUWEIzanVCUEdlTjhsalJJX3JxQzhMOA?oc=5","date":"2025-12-25","type":"pipeline","source":"Benzinga","summary":"Dynavax Technologies (DVAX) Shares Are Trending Overnight — Here's Why - Benzinga","headline":"Dynavax Technologies (DVAX) Shares Are Trending Overnight — Here's Why","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQZ1BfUTVMbEswQjNqQ1BvQURVX09jaUxqM1g3bXVZVmFkMFNKenA4c2l4alpuQUQtZTQ4QUxqc05yd2hzMmsza0hucmlXelFQYXZQa00tX29GeVlvN0JQcUJYVXVwbXpIRXJMRmNlRnVGQnhrSzFvUlV5R2VUS09zc3J3T05rU0lVOHNzTFFfNEtGYmg1aFNmNmtVZEY4M2FIUU11RjVkSzJ0U3ByWEtxSmYxSjRvanc?oc=5","date":"2025-12-24","type":"deal","source":"reuters.com","summary":"Sanofi pushes ahead on adult vaccines with $2.2 billion Dynavax deal - reuters.com","headline":"Sanofi pushes ahead on adult vaccines with $2.2 billion Dynavax deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPVlVoTUtsV1J3eHRYSmpaVVFMQlc5bFpnMVE4ZkM0QVBLQkpKMXNLWFpndUlORG1CdE5KUElMZW40Y3dRRTRqU09HREZ1Rld5dmlIRU0xTDB0WFBvZThvRzJfc1VUQ0k3SFNFNXpYdWZjWFpUcERpM05WU3pTMGNtUGhuR0xLeTc4ekRN?oc=5","date":"2025-12-24","type":"deal","source":"The Pharma Letter","summary":"Sanofi to acquire vaccine maker Dynavax - The Pharma Letter","headline":"Sanofi to acquire vaccine maker Dynavax","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxOQlZLWE1pdTZTalBNS0E0aTR2Q2oxWFBDeXdta241X3ZpM1Z0cHJmcGNyWm5paDNzWmNrYmFIcFZhOHhRLURfQk9GNU93UjNLWGtNZ1RVUTl5YVlNcmZhSDMwbXh1by1ob3NkM3paX2UtcTV2Y042OGU2UlhfUl9tZ09mVDAzaE5mRzdyb3gtbUltVER4M3hveEJVUjZMZGNVMGRwNlM1ZkUtcldrajRJWTFwRHZDcmJ2OHJUbGlUWVZ1cUJ6eEtYWWZ5Vl9QZXNveENwekpITE96MkZCZUpQUnRSUTFxVDlWc1BDdnVTZ3NrRjNFVEdN?oc=5","date":"2025-12-24","type":"deal","source":"The Chronicle-Journal","summary":"Sanofi Acquires Dynavax in $2.2 Billion Christmas Eve Deal, Sending Shares Soaring - The Chronicle-Journal","headline":"Sanofi Acquires Dynavax in $2.2 Billion Christmas Eve Deal, Sending Shares Soaring - The Chronicle","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE56M1R6UDdwem9DblJWZ1U4TGpWQ055OEdpSVU1c2J4UnZoamF0Z2stWkdxN3QyeVJvM2JSOGNtRHBxUnFSUzFmOG5fQUluRzNTTjRLclQ2aG1NcmJfOWhkOVlZMkpQVGZNR0dEX1ZjaDF3N1RCb1E3Zm1Wd1I?oc=5","date":"2025-12-24","type":"pipeline","source":"The Motley Fool","summary":"Why Dynavax Stock Soared Today - The Motley Fool","headline":"Why Dynavax Stock Soared Today","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxObEpVaHRhQ2QtbE5GMENoaWl1blprVWZPWUNoOXF0RGlfY1ZrOTJLcXpNX25kWFRDUktfb002a1JIOUk4cU8zV09oZXdnMF9DOG1UU3pEYkdxazk5eE50dU5Od0VjaXVvNlNrVkZVUS1qU2RvdDJVMklTVXN1bmpfcWUyazExdG8?oc=5","date":"2025-07-06","type":"deal","source":"Yahoo Finance","summary":"Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31 - Yahoo Finance","headline":"Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31","sentiment":"neutral"}],"patents":[{"drugName":"Heplisav-B","drugSlug":"hepatitis-b-vaccine","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":1200000000}],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["GSK","Merck & Co.","Biontech"],"therapeuticFocus":["Vaccines","Adjuvant Technology"],"financials":{"source":"sec_edgar+yahoo","revenue":327000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":327000,"period":"2017-12-31"},{"value":21000,"period":"2017-12-31"},{"value":53000,"period":"2017-09-30"},{"value":105000,"period":"2017-06-30"},{"value":148000,"period":"2017-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":61550000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":27309000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":986256000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":405,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":15.5,"previousClose":15.5,"fiftyTwoWeekHigh":15.73,"fiftyTwoWeekLow":0,"fiftyTwoWeekRange":"","fiftyDayAverage":13.85,"twoHundredDayAverage":11.24,"beta":0.93,"enterpriseValue":1461495040,"forwardPE":47,"priceToBook":3.41,"priceToSales":5.51,"enterpriseToRevenue":4.42,"enterpriseToEbitda":60.37,"pegRatio":0,"ebitda":24211000,"ebitdaMargin":7.3,"freeCashflow":51301624,"operatingCashflow":90632000,"totalDebt":289223008,"debtToEquity":54.1,"currentRatio":7.62,"returnOnAssets":1.2,"returnOnEquity":-7.1,"analystRating":"","recommendationKey":"strong_buy","numberOfAnalysts":1,"targetMeanPrice":16,"targetHighPrice":16,"targetLowPrice":16,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.8,"institutionHeldPercent":101.5,"sharesOutstanding":113684064,"floatShares":100340809,"sharesShort":9793176,"shortRatio":2.81,"shortPercentOfFloat":8.6,"epsTrailing":-0.37,"epsForward":0,"revenuePerShare":2.7,"bookValue":4.55,"officers":[{"age":46,"name":"Mr. Ryan  Spencer","title":"CEO & Director"},{"age":41,"name":"Ms. Kelly  MacDonald CPA","title":"Senior VP & CFO"},{"age":63,"name":"Mr. David F. Novack","title":"Senior VP & COO"},{"age":60,"name":"Mr. John L. Slebir Esq.","title":"Senior VP & General Counsel"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"http://investors.dynavax.com/index.cfm","website":"https://www.dynavax.com","phone":"510 848 5100"}}